featured
Planned Discontinuation or Continuous Treatment of Oxaliplatin After Six Cycles of Modified FOLFOX6 Plus Panitumumab in Patients With Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
SAPPHIRE: A Randomised Phase II Study of Planned Discontinuation or Continuous Treatment of Oxaliplatin After Six Cycles of Modified FOLFOX6 Plus Panitumumab in Patients With Colorectal Cancer
Eur. J. Cancer 2019 Sep 01;119(xx)158-167, Y Munemoto, M Nakamura, M Takahashi, M Kotaka, H Kuroda, T Kato, N Minagawa, S Noura, M Fukunaga, H Kuramochi, T Touyama, T Takahashi, K Miwa, H Satake, S Kurosawa, T Miura, H Mishima, J Sakamoto, K Oba, N NagataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.